Alexza Pharma (ALXA) Reports Q1 Loss of $0.16
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil settles up 2% after Trump rejects return to Iran ceasefire deal terms
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Revolution Medicines prices RASONQUE at $39,800 per month
Alexza Reports 2016 First Quarter Financial Results
May 11, 2016 5:00 PM EDTMOUNTAIN VIEW, Calif., May 11, 2016 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA, "Alexza", or the "Company") today reported financial results for the quarter ended March 31, 2016. The net loss for the first quarter was $3.4 million compared to $0.4 million during the same quarter in 2015. At March 31, 2016, Alexza had consolidated cash and cash equivalents of $4.5 million.Â
Alexza believes that, based on its cash and cash equivalent balances at March 31, 2016, the additional $2.3 million drawn in April and May 2016 under the amended and restated note issued May 9, 2016, and the Company's expected cash usage, it has sufficient capital resources to meet its... More
